Asapiprant

N/A

Report date: 2026/02/04 20:00:52
NME

Base Information

Drug NameAsapiprant
Drug Alias NameAsapiprantum艾沙匹仑阿萨匹仑S-555739BGE-175
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin D2 receptor antagonists
TargetsProstaglandin D2 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Rhinitis, Allergic, Seasonal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesArgentinaBrazil
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShionogi & Co LtdBioAge Labs Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Rhinitis, Allergic, Seasonal

Other Information

ATC CodeN/A
Related LinksN/A